CA3207821A1 - Orthogonal mutations for heterodimerization - Google Patents
Orthogonal mutations for heterodimerization Download PDFInfo
- Publication number
- CA3207821A1 CA3207821A1 CA3207821A CA3207821A CA3207821A1 CA 3207821 A1 CA3207821 A1 CA 3207821A1 CA 3207821 A CA3207821 A CA 3207821A CA 3207821 A CA3207821 A CA 3207821A CA 3207821 A1 CA3207821 A1 CA 3207821A1
- Authority
- CA
- Canada
- Prior art keywords
- domain
- amino acid
- sequence
- domains
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063123915P | 2020-12-10 | 2020-12-10 | |
| US63/123,915 | 2020-12-10 | ||
| PCT/US2021/062951 WO2022125986A1 (en) | 2020-12-10 | 2021-12-10 | Orthogonal mutations for heterodimerization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3207821A1 true CA3207821A1 (en) | 2022-06-16 |
Family
ID=81974005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3207821A Pending CA3207821A1 (en) | 2020-12-10 | 2021-12-10 | Orthogonal mutations for heterodimerization |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12312418B2 (https=) |
| EP (1) | EP4259194A4 (https=) |
| JP (1) | JP2024500354A (https=) |
| KR (1) | KR20230118612A (https=) |
| CN (1) | CN116867514A (https=) |
| AU (1) | AU2021397322A1 (https=) |
| CA (1) | CA3207821A1 (https=) |
| IL (1) | IL303518A (https=) |
| MX (1) | MX2023006899A (https=) |
| WO (1) | WO2022125986A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023245021A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof |
| WO2025129132A1 (en) * | 2023-12-14 | 2025-06-19 | Invenra Inc. | Multispecific binding agents that target ctla4 and/or cd25 and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013537416A (ja) * | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法 |
| ES2758994T3 (es) * | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| JP6385357B2 (ja) * | 2012-11-27 | 2018-09-05 | アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ | 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途 |
| HK1220465A1 (zh) * | 2013-03-06 | 2017-05-05 | Merrimack Pharmaceuticals, Inc. | 抗c-met串联fc双特异性抗体 |
| WO2016130516A1 (en) * | 2015-02-09 | 2016-08-18 | Research Development Foundation | Engineered immunoglobulin fc polypeptides displaying improved complement activation |
| US10696722B2 (en) * | 2016-08-10 | 2020-06-30 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
| CN110177805B (zh) * | 2016-10-19 | 2024-04-02 | 英温拉公司 | 抗体构建体 |
| WO2018148447A1 (en) * | 2017-02-08 | 2018-08-16 | Adimab, Llc | Antibody heavy chain variable domains targeting the nkg2d receptor |
| JP7438942B2 (ja) * | 2017-10-30 | 2024-02-27 | エフ． ホフマン－ラ ロシュ アーゲー | 単一特異性抗体から多重特異性抗体をインビボ生成させるための方法 |
| US20210163594A1 (en) * | 2018-04-17 | 2021-06-03 | Invenra Inc. | Binding molecules |
| KR102870868B1 (ko) * | 2018-06-01 | 2025-10-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| JP7812230B2 (ja) * | 2019-04-25 | 2026-02-09 | エフ． ホフマン－ラ ロシュ アーゲー | ポリペプチド鎖交換による抗体由来ポリペプチドの生成 |
| AU2021224883A1 (en) * | 2020-02-20 | 2022-09-29 | Invenra Inc. | Bispecific GD2 and B7H2 binding molecules and methods of use |
-
2021
- 2021-12-10 CA CA3207821A patent/CA3207821A1/en active Pending
- 2021-12-10 MX MX2023006899A patent/MX2023006899A/es unknown
- 2021-12-10 KR KR1020237022864A patent/KR20230118612A/ko active Pending
- 2021-12-10 CN CN202180091688.7A patent/CN116867514A/zh active Pending
- 2021-12-10 US US17/548,375 patent/US12312418B2/en active Active
- 2021-12-10 WO PCT/US2021/062951 patent/WO2022125986A1/en not_active Ceased
- 2021-12-10 AU AU2021397322A patent/AU2021397322A1/en active Pending
- 2021-12-10 JP JP2023535392A patent/JP2024500354A/ja active Pending
- 2021-12-10 IL IL303518A patent/IL303518A/en unknown
- 2021-12-10 EP EP21904522.6A patent/EP4259194A4/en active Pending
-
2025
- 2025-04-25 US US19/190,527 patent/US20260078202A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021397322A9 (en) | 2024-06-20 |
| WO2022125986A1 (en) | 2022-06-16 |
| AU2021397322A1 (en) | 2023-07-06 |
| KR20230118612A (ko) | 2023-08-11 |
| EP4259194A1 (en) | 2023-10-18 |
| JP2024500354A (ja) | 2024-01-09 |
| US20260078202A1 (en) | 2026-03-19 |
| US20220363782A1 (en) | 2022-11-17 |
| CN116867514A (zh) | 2023-10-10 |
| IL303518A (en) | 2023-08-01 |
| EP4259194A4 (en) | 2025-03-19 |
| US12312418B2 (en) | 2025-05-27 |
| MX2023006899A (es) | 2023-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107207592B (zh) | 结构域交换的抗体 | |
| US10562982B2 (en) | Methods for producing Fabs and bi-specific antibodies | |
| CA2892623C (en) | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof | |
| US20260078202A1 (en) | Orthogonal mutations for heterodimerization | |
| JP7123063B2 (ja) | 抗体ドメインの好ましい対形成 | |
| US20240368311A1 (en) | Bispecific antigen binding construct |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241128 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241128 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241128 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251112 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251112 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251201 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251201 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251201 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251208 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260129 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260129 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260129 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260129 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260129 |